We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ABMD - Replacement Heart System
ABMD 265.85+0.8%3:55 PM EDT

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext  
From: tech10111/8/2019 7:24:07 PM
   of 147
$ABMD (ABioMed, Inc)
Does Impella (from ABMD)Affect Predicted AKI Risk?
Study Shows a 78% Risk Decrease in Overall Incidence of Post-procedural AKI
October 30, 2019
Dr. Michael Flaherty presents a more contemporary analysis of acute kidney injury (AKI) in patients undergoing high-risk PCI with Impella support.
The Impella 5.5 with SmartAssist is a minimally invasive, forward flow, fully unloading heart pump designed for surgical use, delivering peak flows of >6 L/min, allowing the heart to rest; enabling heart recovery. This next generation heart pump is designed to improve patient outcomes by using real-time intelligence to optimize positioning, managing and weaning of the Impella device for better patient care. The Impella 5.5 heart pump pulls blood from the left ventricle through an inlet area near the tip and expels blood from the catheter into the ascending aorta. New hemodynamic sensor technology allows for repositioning in the ICU without the need for imaging*; the optical sensor senses aortic pressure while the micro-axial motor senses the blood flow (pressure) between the aorta and the left ventricle. *For ventricularized pumps
Insertion: The Impella 5.5 with SmartAssist can be inserted through the axillary artery or anterior aorta and across the valve and into the left ventricle.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10PreviousNext